Marketed as Exdensur, the ultra-long-acting biologic is the first of its kind, requiring only two injections per year to ...

The FDA has approved Exdensur (depemokimab-ulaa) as an add-on maintenance treatment for people with severe asthma.

A monthly injection could enable severe asthma patients to stop taking daily steroid tablets without affecting their symptoms, a new trial has found. The drug, Tezepelumab (also known as Tezspir and ...

GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved Exdensur ...

Asthma care continues to develop, particularly in how treatment and long-term management are approached. This article outlines current treatment and management recommendations for patients aged 12 and ...

FDA nod boosts GSK's ultra-long-acting asthma therapy, with global rollout and multi-condition expansion on the horizon.

In the first randomized controlled trial to investigate the use of a 2-in-1 inhaler as the sole reliever therapy for children aged 5 to 15, an international team found the combined treatment to be ...

Findings from a trial comparing the real-world effectiveness of asthma inhalers could reshape how children with asthma are treated. In the first randomised controlled trial to investigate the use of a ...

Indiana University School of Medicine researchers are taking a closer look at how young patients respond to biologic ...

September brings many asthma triggers that cause more asthma attacks, emergency room visits, and hospital stays than any other during the year. Asthma is a disease that narrows the airways and makes ...

A new trial at Sheffield Children's Hospital will test whether a combined inhaler can better control asthma symptoms and attacks in youngsters. The study, which focuses on children aged six to 11, ...

"This new drug could be a game changer for future treatment of asthma" - Professor Chris Brightling, NIHR Senior Research Fellow at the University of Leicester The first new asthma pill for nearly 20 ...